Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days.

“Today represents an important step in our transition to private ownership under Novo Holdings, a leading life sciences investment firm,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “As we approach transaction close, I want to thank the Catalent team for all their hard work and share my excitement for our company’s bright future. With the support of Novo Holdings and access to additional resources, Catalent will be well-positioned to drive innovation and enhance offerings for the benefit of customers and the patients they serve, ultimately accelerating our strategy to create value for stakeholders.”

“We are pleased to have achieved this latest milestone, which we believe reflects the significant benefits the proposed transaction is expected to deliver,” said Jonathan Levy, Senior Partner, Novo Holdings. “As we near close, we are enthusiastic about partnering with and supporting the Catalent team in its mission to drive innovation in the healthcare system and improve patient outcomes.”

For additional information associated with the transaction, please visit transaction.catalent.com.

Advisors
Citi and J.P. Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Catalent and Jones Day served as legal advisor to the Catalent Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP served as legal advisors to Novo Nordisk.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk